ArticleFrontiers in immunology2022
PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06639971 (Retrospective Cohort Study on the Therapeutic Effects of Immunotherapy and Targeted Therapy Combined With or Without Radiotherapy for Hepatocellular Carcinoma Based on Real-world Data), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retrospective Cohort Study on the Therapeutic Effects of Immunotherapy and Targeted Therapy Combined With or Without Radiotherapy for Hepatocellular Carcinoma Based on Real-world Data
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pooled it
- Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma.Hepatology international · 2026Article
- Combining External Beam Radiotherapy and Immunotherapy for the Treatment of Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2026Review
- The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC.The oncologist · 2026Article
- Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.The oncologist · 2026Article
- Integrative Genomic Analysis Reveals Pseudouridine Modification-Related Gene Signatures Associated With Prognosis and Therapeutic Response Patterns in Hepatocellular Carcinoma.International journal of genomics · 2026Article
- Efficacy and Safety of Radiotherapy Combined with PD-1 Inhibitors and Targeted Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective, Real-World Multicenter Study.Journal of hepatocellular carcinoma · 2026Article
- Artificial intelligence-based personalized treatment strategies for unresectable hepatocellular carcinoma: integrating HSP90α for prognosis and survival prediction.NPJ digital medicine · 2025Article
- A nomogram for predicting overall survival in advanced hepatocellular carcinoma patients receiving radiotherapy combined with targeted therapy: a multicenter retrospective study.Translational cancer research · 2025Article
- Safety and toxicity risks of radiotherapy combined with PD-1/PD-L1 inhibitors: A comprehensive review.iScience · 2025Review
- Using machine learning methods to investigate the impact of age on the causes of death in patients with early intrahepatic cholangiocarcinoma who underwent surgery.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Radiotherapy with targeted and immunotherapy improved overall survival and progression-free survival for hepatocellular carcinoma with portal vein tumor thrombosis.The oncologist · 2025Article
- Machine Learning Radiomics for Predicting Response to MR-Guided Radiotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study.Journal of hepatocellular carcinoma · 2025Article
- Artificial intelligence-based evaluation of prognostic benefits from immunotherapy plus targeted therapy with or without radiotherapy or TACE in advanced hepatocellular carcinoma.Frontiers in oncology · 2025Article
- A Review on Nanotechnologically Derived Phytomedicines for the Treatment of Hepatocellular Carcinoma: Recent Advances in Molecular Mechanism and Drug Targeting.Current drug targets · 2025Review
- Hypofractionated and intensity-modulated radiotherapy combined with systemic therapy in metastatic hepatocellular carcinoma: A case report.World journal of clinical oncology · 2024Article
- Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study.Japanese journal of clinical oncology · 2024Article
- Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases.Translational cancer research · 2024Article
- Causal relationship between immune cells and hepatocellular carcinoma: a Mendelian randomisation study.Journal of Cancer · 2024Article
- Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whether intensity-modulated radiotherapy (IMRT) can enhance the efficacy of the programmed death (PD)-1 inhibitors combined with anti-angiogenic therapy for hepatocellular carcinoma (HCC) is unclear. Therefore, we conducted this multicenter retrospective study to investigate the efficacy of the combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT. Methods: From April 2019 to March 2022, a total of 197 patients with HCC [combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT (triple therapy group), 54; PD-1 inhibitors plus anti-angiogenic therapy (control group), 143] were included in our study. Propensity score matching (PSM) was applied to identify two groups with similar baselines. The objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) of the two groups were compared before and after matching. Results: Prior to PSM, the triple therapy group had higher ORR (42.6% vs 24.5%, Conclusions: The combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT for HCC is a promising regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.